As per the deal, Clearstone will provide LabCorp with central laboratories and clinical trials management system Apollo CLPM, which provides clients with real-time access to automate sample stability monitoring across all lab sites.
The new company will have the biomarker assay portfolio with testing platforms in areas such as pharmacogenomics, microbiology, immunohistochemistry, allergy testing, cytogenetics and flow cytometry.
Chairman and CEO David King said this acquisition combines the complementary strengths of the Clearstone and LabCorp clinical trials businesses to support drug development.
"This transaction extends our service capabilities in geographies such as Asia Pacific, and advances the company’s companion diagnostics and personalized medicine strategy," King said.